EGFR and adenocarcinoma: The rate of detected EGFR mutation in the adenocarcinoma subgroup (n = 49) was 40.8%, which was significantly higher than 7.9% in the patients with squamous cell carcinomas and 14.3% in the NSCLC NOS.